COSCIENS Biopharma Inc.
CSCI
$3.46
-$0.09-2.54%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -13.93% | -46.74% | -7.30% | 19.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -13.93% | -46.74% | -7.30% | 19.61% |
| Cost of Revenue | -- | 226.69% | 22.98% | 293.02% | 3,747.77% |
| Gross Profit | -- | -92.93% | -66.39% | -91.95% | -87.14% |
| SG&A Expenses | -- | -72.63% | -57.47% | -100.09% | -56.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -64.72% | -31.89% | -86.55% | -72.43% |
| Operating Income | -- | 110.02% | 24.20% | 127.65% | 106.18% |
| Income Before Tax | -- | 92.46% | 37.96% | 97.53% | 104.15% |
| Income Tax Expenses | -- | -465.81% | -729.49% | -1,864.10% | -- |
| Earnings from Continuing Operations | -- | 102.73% | 40.89% | 105.04% | 109.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 102.73% | 40.89% | 105.04% | 109.42% |
| EBIT | -- | 110.02% | 24.20% | 127.65% | 106.18% |
| EBITDA | -- | 132.00% | 27.72% | 142.95% | 117.97% |
| EPS Basic | -- | 79.33% | 44.43% | 84.10% | 89.04% |
| Normalized Basic EPS | -- | 81.76% | 21.01% | 89.65% | 79.43% |
| EPS Diluted | -- | 79.32% | 44.43% | 84.09% | 89.04% |
| Normalized Diluted EPS | -- | 81.76% | 21.01% | 89.65% | 79.43% |
| Average Basic Shares Outstanding | -- | 47.48% | 11.53% | 57.68% | 78.22% |
| Average Diluted Shares Outstanding | -- | 47.48% | 11.53% | 57.68% | 78.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |